Quanterix

137 articles with Quanterix

• Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares

  8/13/2019

  Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares

• Quanterix Prices Public Offering of Common Stock

  8/9/2019

  Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share.

• Quanterix Corporation Releases Operating Results for Second Quarter 2019

  8/6/2019

  $13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increase

• Quanterix to Present at the Canaccord Genuity 39th Annual Growth Conference

  7/31/2019

  Hrusovsky, who will also share remarks at an investor dinner the prior evening hosted by Canaccord Genuity to discuss company momentum in advancing Alzheimer’s treatments and diagnoses, will also be available for one-on-one meetings during the conference.

• Quanterix to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, August 6, 2019

  7/30/2019

  The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

• Uman Diagnostics And Bio-Techne Announce License And Supply Agreement For Neurofilament Light Assay

  7/23/2019

  Under the terms of the agreement, Uman Diagnostics will supply Nf-L antibodies to Bio-Techne for use in its proprietary Simple Plex™ immunoassays on Ella.

• Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier

  6/26/2019

  Quanterix Corporation announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock.

• Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention

  6/4/2019

  Chairman and CEO Kevin Hrusovsky to present at BIO and provide details about the HD-X launch and vision for continuing to pioneer disruption in healthcare with digital biomarkers

• Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms

  5/29/2019

  World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accommodate growing pharma services business

• Quanterix Corporation Releases Operating Results for First Quarter 2019

  5/9/2019

  Quanterix Corporation announced financial results for the three months ended March 31, 2019.

• Quanterix Appoints Amol Chaubal as Chief Financial Officer

  3/28/2019

  Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth

• Quanterix to Release Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Thursday, March 7, 2019

  2/26/2019

  Quanterix Corporation announced that it will release its financial results for fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019.

• Quanterix to Present at Multiple Upcoming Healthcare Conferences

  2/21/2019

  Chief Executive Officer will speak at the Leerink Partners Global Healthcare Conference and the Cowen and Company Health Care Conference

• Quanterix to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum

  11/13/2018

  Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity Medical Technologies & Diagnostic Forum,

• Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

  11/7/2018

  Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products

• Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology

  11/7/2018

  Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research

• Quanterix Corporation Releases Operating Results for Third Quarter 2018

  11/1/2018

  85% revenue growth

• Quanterix to Release Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 1, 2018

  10/25/2018

  Quanterix Corporation today announced that it will release its financial results for third quarter 2018 after the close of trading on Thursday, November 1, 2018.

• Quanterix Announces Collaboration with OncoGenesis to Develop Cervical Screening Test

  10/22/2018

  Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection

• Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018

  10/9/2018

  International multiple sclerosis conference features 35 new studies using Simoa technology demonstrating potential of Neurofilament light chain (NfL) as a reliable and sensitive disease biomarker